GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man

N. J. Talley, S. F. Phillips, A. Haddad, Laurence J Miller, C. Twomey, A. R. Zinsmeister, R. L. MacCarty, A. Ciociola

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

The newly recognized class of 5-hydroxytryptamine receptors (5HT3) may be involved in the induction of nausea, since their pharmacological antagonists are effective against emesis induced by chemotherapy. 5HT3 receptors are present on enteric neurons, and 5HT3 blockers may produce mild constipation; we thus hypothesized that 5HT3 receptors would modulate colonic motility. To determine if GR 38032F, a selective 5HT3 antagonist known to have antiemetic effects, influences colonic transit in health, a randomized, double-blind, placebo-controlled crossover study was performed. Using a radiopaque marker technique, colonic transit was quantified in 39 healthy volunteers (19 men, 20 nonpregnant women) 18-70 years of age. On a standard 25-g fiber diet, 16 mg of GR 38032F was given orally thrice daily. Gastrointestinal peptides (peptide YY, human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, substance P) were also measured in plasma fasting and postprandially. Mean total colonic transit time on placebo was 27.8 hr, while on GR 38032F it was 39.1 hr (P<0.0005). Transit times through the left colon (P<0.0005) and rectosigmoid (P<0.05) were prolonged by the drug, but right colonic transit was not significantly altered. Transit times did not correlate with age or gender, but subjects with shorter transit times were significantly more affected than were those with longer transit times. The peak release of peptide YY was minimally decreased following GR 38032F (P<0.01), but the peak and integrated postprandial responses of human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, and substance P were not significantly altered by the drug. We conclude that 5HT3 receptors may be involved in the regulation of colonic transit in healthy man.

Original languageEnglish (US)
Pages (from-to)477-480
Number of pages4
JournalDigestive Diseases and Sciences
Volume35
Issue number4
DOIs
StatePublished - Apr 1990

Fingerprint

Ondansetron
Motilin
Peptide YY
Neurotensin
Cholecystokinin
Gastrins
Substance P
Placebos
Antiemetics
Serotonin Receptors
Constipation
Pharmaceutical Preparations
Cross-Over Studies
Nausea
Vomiting
Fasting
Healthy Volunteers
Colon
Pharmacology
Diet

Keywords

  • 5HT antagonists
  • colonic transit
  • gastrointestinal peptides

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Talley, N. J., Phillips, S. F., Haddad, A., Miller, L. J., Twomey, C., Zinsmeister, A. R., ... Ciociola, A. (1990). GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Digestive Diseases and Sciences, 35(4), 477-480. https://doi.org/10.1007/BF01536922

GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. / Talley, N. J.; Phillips, S. F.; Haddad, A.; Miller, Laurence J; Twomey, C.; Zinsmeister, A. R.; MacCarty, R. L.; Ciociola, A.

In: Digestive Diseases and Sciences, Vol. 35, No. 4, 04.1990, p. 477-480.

Research output: Contribution to journalArticle

Talley, NJ, Phillips, SF, Haddad, A, Miller, LJ, Twomey, C, Zinsmeister, AR, MacCarty, RL & Ciociola, A 1990, 'GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man', Digestive Diseases and Sciences, vol. 35, no. 4, pp. 477-480. https://doi.org/10.1007/BF01536922
Talley, N. J. ; Phillips, S. F. ; Haddad, A. ; Miller, Laurence J ; Twomey, C. ; Zinsmeister, A. R. ; MacCarty, R. L. ; Ciociola, A. / GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. In: Digestive Diseases and Sciences. 1990 ; Vol. 35, No. 4. pp. 477-480.
@article{65a253f12ad8446394aeb8cd56567219,
title = "GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man",
abstract = "The newly recognized class of 5-hydroxytryptamine receptors (5HT3) may be involved in the induction of nausea, since their pharmacological antagonists are effective against emesis induced by chemotherapy. 5HT3 receptors are present on enteric neurons, and 5HT3 blockers may produce mild constipation; we thus hypothesized that 5HT3 receptors would modulate colonic motility. To determine if GR 38032F, a selective 5HT3 antagonist known to have antiemetic effects, influences colonic transit in health, a randomized, double-blind, placebo-controlled crossover study was performed. Using a radiopaque marker technique, colonic transit was quantified in 39 healthy volunteers (19 men, 20 nonpregnant women) 18-70 years of age. On a standard 25-g fiber diet, 16 mg of GR 38032F was given orally thrice daily. Gastrointestinal peptides (peptide YY, human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, substance P) were also measured in plasma fasting and postprandially. Mean total colonic transit time on placebo was 27.8 hr, while on GR 38032F it was 39.1 hr (P<0.0005). Transit times through the left colon (P<0.0005) and rectosigmoid (P<0.05) were prolonged by the drug, but right colonic transit was not significantly altered. Transit times did not correlate with age or gender, but subjects with shorter transit times were significantly more affected than were those with longer transit times. The peak release of peptide YY was minimally decreased following GR 38032F (P<0.01), but the peak and integrated postprandial responses of human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, and substance P were not significantly altered by the drug. We conclude that 5HT3 receptors may be involved in the regulation of colonic transit in healthy man.",
keywords = "5HT antagonists, colonic transit, gastrointestinal peptides",
author = "Talley, {N. J.} and Phillips, {S. F.} and A. Haddad and Miller, {Laurence J} and C. Twomey and Zinsmeister, {A. R.} and MacCarty, {R. L.} and A. Ciociola",
year = "1990",
month = "4",
doi = "10.1007/BF01536922",
language = "English (US)",
volume = "35",
pages = "477--480",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man

AU - Talley, N. J.

AU - Phillips, S. F.

AU - Haddad, A.

AU - Miller, Laurence J

AU - Twomey, C.

AU - Zinsmeister, A. R.

AU - MacCarty, R. L.

AU - Ciociola, A.

PY - 1990/4

Y1 - 1990/4

N2 - The newly recognized class of 5-hydroxytryptamine receptors (5HT3) may be involved in the induction of nausea, since their pharmacological antagonists are effective against emesis induced by chemotherapy. 5HT3 receptors are present on enteric neurons, and 5HT3 blockers may produce mild constipation; we thus hypothesized that 5HT3 receptors would modulate colonic motility. To determine if GR 38032F, a selective 5HT3 antagonist known to have antiemetic effects, influences colonic transit in health, a randomized, double-blind, placebo-controlled crossover study was performed. Using a radiopaque marker technique, colonic transit was quantified in 39 healthy volunteers (19 men, 20 nonpregnant women) 18-70 years of age. On a standard 25-g fiber diet, 16 mg of GR 38032F was given orally thrice daily. Gastrointestinal peptides (peptide YY, human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, substance P) were also measured in plasma fasting and postprandially. Mean total colonic transit time on placebo was 27.8 hr, while on GR 38032F it was 39.1 hr (P<0.0005). Transit times through the left colon (P<0.0005) and rectosigmoid (P<0.05) were prolonged by the drug, but right colonic transit was not significantly altered. Transit times did not correlate with age or gender, but subjects with shorter transit times were significantly more affected than were those with longer transit times. The peak release of peptide YY was minimally decreased following GR 38032F (P<0.01), but the peak and integrated postprandial responses of human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, and substance P were not significantly altered by the drug. We conclude that 5HT3 receptors may be involved in the regulation of colonic transit in healthy man.

AB - The newly recognized class of 5-hydroxytryptamine receptors (5HT3) may be involved in the induction of nausea, since their pharmacological antagonists are effective against emesis induced by chemotherapy. 5HT3 receptors are present on enteric neurons, and 5HT3 blockers may produce mild constipation; we thus hypothesized that 5HT3 receptors would modulate colonic motility. To determine if GR 38032F, a selective 5HT3 antagonist known to have antiemetic effects, influences colonic transit in health, a randomized, double-blind, placebo-controlled crossover study was performed. Using a radiopaque marker technique, colonic transit was quantified in 39 healthy volunteers (19 men, 20 nonpregnant women) 18-70 years of age. On a standard 25-g fiber diet, 16 mg of GR 38032F was given orally thrice daily. Gastrointestinal peptides (peptide YY, human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, substance P) were also measured in plasma fasting and postprandially. Mean total colonic transit time on placebo was 27.8 hr, while on GR 38032F it was 39.1 hr (P<0.0005). Transit times through the left colon (P<0.0005) and rectosigmoid (P<0.05) were prolonged by the drug, but right colonic transit was not significantly altered. Transit times did not correlate with age or gender, but subjects with shorter transit times were significantly more affected than were those with longer transit times. The peak release of peptide YY was minimally decreased following GR 38032F (P<0.01), but the peak and integrated postprandial responses of human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, and substance P were not significantly altered by the drug. We conclude that 5HT3 receptors may be involved in the regulation of colonic transit in healthy man.

KW - 5HT antagonists

KW - colonic transit

KW - gastrointestinal peptides

UR - http://www.scopus.com/inward/record.url?scp=0025219706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025219706&partnerID=8YFLogxK

U2 - 10.1007/BF01536922

DO - 10.1007/BF01536922

M3 - Article

C2 - 2138532

AN - SCOPUS:0025219706

VL - 35

SP - 477

EP - 480

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 4

ER -